Featured Articles

  1. Precision Medicine: Targeted Cancer Therapies 10/2/2025

    Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

  2. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

    Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

  3. Benefits Of Working With Catalyst Oncology Versus A Large Generalist CRO 10/2/2025

    Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

  4. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

    By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

  5. The Evolving Landscape Of Oncology Drug Development 9/17/2025

    Explore the novel drug modalities poised to revolutionize oncology and improve patient outcomes.

  6. The Resurgence Of Antibody-Drug Conjugates 9/1/2025

    As advancements in ADC technology and clinical trial methodologies progress, Antibody-Drug Conjugates (ADCs) are poised to become pivotal in precision oncology.

  7. Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape 9/1/2025

    Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.

  8. Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, And Proven Strategies 8/29/2025

    Ovarian cancer remains one of the deadliest gynecologic malignancies. Successful clinical trials in this space demand deep therapeutic expertise, operational agility, and global coordination.

  9. Optimizing Global Early-Phase Oncology Trials 8/29/2025

    By integrating strong partnerships, local expertise, and predictive analytics, sponsors and CROs can identify and activate the most suitable sites, accelerating trial delivery.